ArticleBiomedica : revista del Instituto Nacional de Salud2026
COVID-19 clinical outcomes in pediatrics: Comparison between immunocompromised and immunocompetent patients in Colombia
Article in Biomedica : revista del Instituto Nacional de Salud, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pediatric patients generally present less severe COVID-19 compared with adults; however, clinical outcomes in immunosuppressed children remain heterogeneous and controversial. Some studies suggest a higher risk of complications, whereas others propose that immunosuppression could attenuate the exaggerated inflammatory response associated with severe disease. Objective: To compare the clinical outcomes of immunosuppressed and immunocompetent pediatric patients hospitalized with COVID-19 in a highcomplexity center in Colombia during the pandemic. Materials and methods: A retrospective cohort study was conducted including patients under 18 years of age hospitalized with confirmed COVID-19 between 2020 and 2023. Clinical characteristics and outcomes were compared between both groups. Descriptive statistics were used, along with chi square or Fisher’s exact tests for categorical variables, and Student’s t test or MannWhitney U test for continuous variables depending on their distribution, with significance set at p < 0.05. Results: A total of 705 patients were analyzed: 124 (17.6%) immunosuppressed and 581 (82.4%) immunocompetent. Immunosuppressed patients had a higher median age (10 vs. 2 years) and higher mortality (4.03% vs. 2.1%; p < 0.001). In contrast, immunocompetent patients more frequently required intubation upon admission (4.6% vs. 0.8%; p = 0.02) and had a longer hospital stay (6 vs. 5 days; p = 0.04). Renal failure was more common among immunosuppressed patients (2.4% vs. 0.3%; p = 0.04). Conclusion: Immunosuppressed pediatric patients did not show greater acute clinical severity in terms of critical care requirements; however, they presented higher mortality. These findings highlight the variability of outcomes according to immunological status and underscore the need for further studies to identify risk factors and potential protective mechanisms in the pediatric population with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.